BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19626541)

  • 1. Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival.
    Paul E; Paul E; Uggla B; Deneberg S; Bengtzen S; Hermansson M; Dahlman I; Rosenquist R; Wiman KG; Nahi H
    Leuk Lymphoma; 2009 Sep; 50(9):1512-8. PubMed ID: 19626541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia.
    Müller-Tidow C; Metzelder SK; Buerger H; Packeisen J; Ganser A; Heil G; Kügler K; Adigüzel G; Schwäble J; Steffen B; Ludwig WD; Heinecke A; Büchner T; Berdel WE; Serve H
    Leukemia; 2004 Apr; 18(4):720-6. PubMed ID: 14973498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
    Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
    Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications].
    Yu MX; Lu Y; Mu QT; Wang Q; Chen ZM; Lou JY; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):544-8. PubMed ID: 24078567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
    Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
    Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of GPX3 is associated with favorable/intermediate karyotypes in de novo acute myeloid leukemia.
    Zhou JD; Wen XM; Zhang YY; Yang L; Ma YJ; Ma JC; Yang J; Guo H; Yao DM; Lin J; Qian J
    Int J Clin Exp Pathol; 2015; 8(3):2384-91. PubMed ID: 26045745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
    Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
    Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
    Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
    Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.
    Nahi H; Lehmann S; Bengtzen S; Jansson M; Möllgård L; Paul C; Merup M
    Leuk Lymphoma; 2008 Mar; 49(3):508-16. PubMed ID: 18297528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype.
    Nasiłowska-Adamska B; Warzocha K; Solarska I; Borg K; Pieńkowska-Grela B; Czyż A
    Eur J Haematol; 2017 Sep; 99(3):255-261. PubMed ID: 28618074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
    Yang WC; Lin PM; Yang MY; Liu YC; Chang CS; Chou WC; Hsu JF; Huang CT; Cho SF; Yu WH; Lin SF
    Leuk Lymphoma; 2013 Aug; 54(8):1614-25. PubMed ID: 23150981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
    Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of HOXB4 in de novo acute myeloid leukemia.
    Umeda S; Yamamoto K; Murayama T; Hidaka M; Kurata M; Ohshima T; Suzuki S; Sugawara E; Kawano F; Kitagawa M
    Hematology; 2012 May; 17(3):125-31. PubMed ID: 22664110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.